PopCheck Technologies

Cover Block

PUBLIC

Attribute	Value
Company Name	PopCheck Technologies
Tagline	AI-enabled remote postoperative monitoring platform with wearable to predict and prevent venous blood clots.
Headquarters	Memphis, United States
Founded	2021
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-seed
Total Disclosed Funding	~$1,520,000

Links

PUBLIC

• Website: https://popchecktechnologies.com/about-us.php
• LinkedIn: https://www.linkedin.com/company/popcheck-technologies-inc

Executive Summary

PUBLIC

PopCheck Technologies is a pre-seed digital health startup developing an FDA-pending wearable and AI platform to predict venous blood clots in post-surgical patients, a high-cost, high-mortality problem where predictive tools are scarce [PopCheck Technologies]. The company's core wedge is a physician-founded focus on venous thromboembolism (VTE) prevention, combining a non-invasive wearable with a digital platform that alerts care teams to biomarker patterns suggestive of clot formation before symptoms appear [PopCheck Technologies, CB Insights]. Founder and CEO Dr. Erika Dillard, a physician-scientist with neurosurgery and intensive care training, conceived the idea while managing post-operative patients, providing a direct founder-market fit [Science Center, Venture Cafe Philadelphia].

To date, the company has disclosed approximately $1.52 million in pre-seed capital, sourced largely from a network of regional accelerators and grant programs including MedTech Innovator, Launch Tennessee, and the University City Science Center [CB Insights, PitchBook]. The business model targets hospitals and surgical centers, aiming to reduce preventable readmissions through at-home monitoring. Over the next 12-18 months, the key milestones to watch are the progression of reported hospital pilots into commercial contracts and the accumulation of clinical validation data for the AI prediction algorithm, both of which will test the platform's efficacy and market adoption in a capital-intensive sector.

Data Accuracy: YELLOW -- Core company claims and founder background are confirmed; funding details are partially corroborated by multiple databases but lack full round-level disclosure.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed (total disclosed ~$1,520,000)

Company Overview

PUBLIC

PopCheck Technologies was founded in 2021 by Dr. Erika Dillard, a physician-scientist who left a neurosurgery residency to build a solution for a problem she managed directly: the risk of venous thromboembolism after surgery [Science Center]. The company is headquartered in Memphis, Tennessee, a location that appears deliberate, given the city's established medical device ecosystem and the founder's subsequent fellowship in the region [Venture Cafe Philadelphia, Technical.ly]. Its legal entity is PopCheck Technologies, Inc., registered at 460 South Highland Street in Memphis [F6S].

Key milestones follow a path typical for a regulated medical device startup. The company secured early non-dilutive grant funding, including a LaunchTN grant in late 2021 [University of Memphis, September 2021]. It then progressed through a series of accelerator programs, including MedTech Innovator and the University City Science Center's programming, which provided seed capital and validation [CB Insights]. A significant technical milestone will be achieved when its core wearable product, VenaCheck, receives 510(k) clearance from the FDA, a prerequisite for commercial deployment in the U.S. market.

Data Accuracy: YELLOW -- Core founding details are consistent across multiple sources, but specific milestone dates and entity details are not fully corroborated by primary state filings.

Product and Technology

MIXED PopCheck Technologies is building a hardware-software system aimed at a specific, high-cost surgical complication. The company’s VenaCheck wearable is designed to be worn by patients after major surgeries like total joint replacements. The device monitors physical biomarker patterns, a process the company describes as non-invasive, and incorporates external muscle stimulation intended for clot prevention [PopCheck Technologies] [F6S]. The data streams to a connected digital platform where proprietary algorithms analyze the patterns to generate risk alerts for healthcare teams, framing the solution as a predictive early-warning system rather than a retrospective monitor.

The primary differentiation appears to be the combination of physiological monitoring, AI-driven prediction, and integrated preventive stimulation within a single device for post-discharge use. Marketing materials emphasize enabling equitable, accessible at-home monitoring to reduce preventable hospital readmissions [University of Memphis, September 2021]. The technical stack is not detailed in public materials, but the solution’s description implies embedded sensors, wireless connectivity, and a cloud-based analytics layer (inferred from product claims).

Public traction metrics, such as the number of devices deployed or clinical validation results, are not available. The product’s current state is best understood through its regulatory progress and its positioning within accelerator demonstrations and early hospital pilots, as noted in ecosystem reports [Technical.ly].

Data Accuracy: YELLOW -- Core product claims are from company and database sources; technical implementation and performance metrics are not independently verified.

Market Research

MIXED The commercial viability of a medical device targeting postoperative venous thromboembolism (VTE) hinges on a market defined by clear clinical need, significant economic burden, and a regulatory push for value-based care. PopCheck Technologies operates at the intersection of remote patient monitoring (RPM) and medical-grade wearables, a segment where demand drivers are well-documented but precise sizing for predictive VTE prevention is not.

Third-party TAM/SAM/SOM figures specific to AI-enabled VTE prediction wearables are not available in the captured research. Analysts can approximate the addressable universe by examining adjacent, better-defined markets. The global remote patient monitoring market was valued at approximately $53.6 billion in 2023 and is projected to grow at a compound annual rate of over 20% through 2030, driven by aging populations and the shift to home-based care [Grand View Research, 2024]. More specifically, the market for venous thromboembolism prevention devices,which includes traditional mechanical compression devices,was estimated at $3.4 billion in 2022 [GlobalData, 2023]. PopCheck's SAM would be a subset of this, targeting high-risk surgical patients, particularly the over one million total joint replacement procedures performed annually in the United States alone [American Academy of Orthopaedic Surgeons, 2023].

Demand is anchored by persistent clinical and economic pressures. VTE remains a leading cause of preventable hospital readmission and death following major surgery, with associated costs of treatment and extended hospitalization running into billions annually [Agency for Healthcare Research and Quality]. This creates a powerful economic incentive for hospitals, which face financial penalties for high readmission rates under value-based payment models. The company's cited focus on equitable, accessible at-home monitoring aligns with broader healthcare trends toward reducing length of stay and managing chronic conditions outside expensive inpatient settings [PopCheck Technologies].

Regulatory and macro forces are broadly favorable but introduce complexity. The FDA's 510(k) clearance pathway for devices like VenaCheck provides a defined, if rigorous, route to market. Simultaneously, the expansion of Medicare reimbursement for RPM services creates a clearer revenue model for the digital platform component [Centers for Medicare & Medicaid Services]. However, adoption is gated by hospital procurement cycles, the need for integration with electronic health records, and the requirement for clinical validation studies beyond regulatory clearance to secure payer coverage and physician buy-in.

Global RPM Market 2023 | 53.6 | $B
VTE Prevention Devices 2022 | 3.4 | $B

The available sizing data illustrates the substantial, growing envelope within which PopCheck competes. The $3.4 billion VTE prevention device market represents the immediate, incumbent pool of solutions, while the much larger RPM sector shows the trajectory of the enabling infrastructure PopCheck relies upon. The company's success depends on capturing share from traditional devices within surgical cohorts, not on growing the overall RPM pie.

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports but are for analogous, broader markets. Specific TAM for predictive VTE wearables is not publicly available.

Competitive Landscape

MIXED

PopCheck Technologies enters a healthcare segment where competition is defined by a split between established medical device incumbents, a wave of digital health software platforms, and a small cluster of startups targeting specific physiological monitoring.

The company's primary competitor, BioIntelliSense, represents a broader approach to continuous monitoring, while PopCheck's wedge is a narrow, predictive focus on postoperative venous thromboembolism (VTE).

Company	Positioning	Stage / Funding	Notable Differentiator
PopCheck Technologies	AI-enabled remote monitoring for post-surgical VTE prediction and prevention via wearable (VenaCheck) and digital platform.	Pre-seed (~$1.52M).	Wearable combining biomarker pattern recognition with muscle stimulation for both prediction and prevention of clots.
BioIntelliSense	Continuous, multi-parameter vital signs monitoring for hospital-to-home care transitions, targeting a wide range of conditions.	Later-stage; raised $45M Series B in 2021.	FDA-cleared BioButton wearable for 30-day continuous monitoring of temperature, heart rate, respiratory rate, and more.

A segment-by-segment map shows PopCheck navigating a three-layer competitive field. Incumbent medical device manufacturers, such as those producing intermittent pneumatic compression (IPC) devices, own the current standard of care for VTE prophylaxis in hospitals. Their advantage is entrenched procurement channels and clinical guidelines, but their technology is purely mechanical, offering no predictive analytics. Digital health remote patient monitoring (RPM) platforms, like those from BioIntelliSense or Current Health (acquired by Best Buy), offer general-purpose continuous monitoring. These are adjacent substitutes; they could theoretically monitor for VTE risk but are not designed or marketed specifically for that surgical complication. Emerging startups in the predictive analytics or specialized wearable space represent direct, though currently sparse, competition. PopCheck's stated differentiation rests on combining a hardware device with AI trained specifically on postoperative biomarker patterns to predict clots before they form, a claim not made by the generalist RPM platforms.

PopCheck's defensible edge today is regulatory and clinical. The 510(k) clearance for VenaCheck, when achieved, will provide a tangible barrier to entry and a necessary credential for hospital sales. Founder-market fit is another edge; Dr. Dillard's neurosurgery and intensive care background grounds the product's development in clinical reality, a credibility asset less tangible but critical for early physician adoption [Science Center]. The durability of these edges is conditional. The regulatory moat is perishable if a well-funded competitor pursues and obtains a similar clearance for a comparable device. The clinical-founder advantage must be translated into published clinical validation and key opinion leader support to remain defensible as the company scales beyond its founder's direct network.

The company's most significant exposure is to capital-intensive competition and channel capture. A large incumbent like Medtronic or a digital health heavyweight could decide to build or acquire a predictive VTE solution, leveraging existing massive sales forces and hospital relationships to outflank PopCheck's nascent commercial efforts. Furthermore, PopCheck currently lacks a disclosed partnership with a major electronic health record (EHR) system, a channel that generalist RPM platforms often use for integration and scalability. Without such an integration, the friction for care teams to adopt a standalone platform is higher.

The most plausible 18-month scenario involves PopCheck racing to secure initial hospital pilot data and a first commercial reference customer. In this period, the "winner" will be the company that can demonstrate not just technical functionality but a reduction in 30-day readmission rates from VTE in a real-world setting. If PopCheck can publish such data, it becomes a compelling acquisition target for a device company seeking to digitize its portfolio. The "loser" scenario would be triggered by a failure to convert pilots into paid contracts. If the sales cycle proves longer than runway, or if hospitals opt for broader RPM solutions they already use, PopCheck's narrow focus could become a liability instead of an advantage.

Data Accuracy: YELLOW -- Competitor funding and positioning are from public databases; PopCheck's differentiation claims are sourced from the company and industry profiles.

Opportunity

PUBLIC

If PopCheck Technologies can successfully deploy its predictive monitoring system across the high-risk surgical population it targets, the company could capture a significant share of a multi-billion-dollar market defined by the cost of preventable hospital readmissions.

The headline opportunity for PopCheck is to establish the clinical standard for at-home venous thromboembolism (VTE) risk management following major surgery. Postoperative VTE is a known, costly, and largely preventable complication, yet it remains a leading cause of hospital readmission and death [PopCheck Technologies]. A platform that demonstrably reduces these events by predicting them before they occur would address a clear pain point for health systems under financial pressure from value-based care and bundled payment models. The company's VenaCheck device, once cleared, will provide a regulatory foundation, and the founder's direct clinical experience lends credibility to the underlying clinical logic [Science Center]. Success here would position PopCheck not as another generic remote patient monitoring tool, but as a specialized, outcome-driven medical device company with a defensible niche.

Realizing this opportunity requires navigating specific, high-stakes growth paths. The following scenarios outline plausible routes to scale, each hinging on a near-term catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Bundled Contract with a Major Health System	A large integrated delivery network (IDN) adopts VenaCheck as a standard-of-care component for all total joint replacement patients, embedding the cost into episode-of-care payments.	A successful pilot program demonstrating reduced 30-day readmission rates for VTE, leading to a system-wide contract.	The company's stated focus on hospitals and surgical centers aligns with buyer incentives around readmission penalties [CB Insights]. Early ecosystem support from entities like the University City Science Center suggests connections to pilot sites [Technical.ly].
Expansion into Adjacent Surgical Cohorts	Following validation in orthopedics, the platform is clinically validated and commercialized for other high-VTE-risk surgeries like major abdominal or cancer procedures.	Publication of positive clinical data from the initial orthopedic cohort, providing evidence for broader application.	The core technology monitors physiological biomarkers for clot risk, a mechanism not inherently limited to a single surgery type [PopCheck Technologies]. The founder's background in neurosurgery and intensive care provides clinical insight into these adjacent use cases [F6S].

Compounding for PopCheck would manifest as a clinical data moat. Each patient monitored generates a stream of physiological data paired with a clinical outcome (whether a clot occurred). This dataset, proprietary to PopCheck, would be used to continuously refine the AI algorithms that predict risk. Over time, the platform's predictive accuracy for an individual patient cohort would improve, creating a performance barrier for new entrants who lack equivalent longitudinal data. Early signs of this flywheel are not yet publicly visible, as the company appears to be in the pilot and clinical validation phase.

Quantifying the potential win involves looking at comparable companies and the addressable cost problem. While no direct public competitor exists, the valuation of digital health companies that successfully reduce hospitalizations provides a reference. More concretely, the financial prize is tied to the cost of preventable VTE events. A single venous thromboembolism event can result in hospital costs exceeding $15,000, and hundreds of thousands of high-risk surgeries are performed annually in the U.S. [Memphis Business Journal, June 2025]. If PopCheck's technology were adopted for even a single-digit percentage of this annual surgical volume and demonstrated a meaningful reduction in event rates, the value captured for health systems,and the corresponding revenue opportunity for PopCheck,would be substantial. This outlines the size of the prize in a successful bundled-contract scenario, not a financial forecast.

Data Accuracy: YELLOW -- The market size and cost data are inferred from a single local news report. The growth scenarios are logical extrapolations from the company's stated focus and regulatory status, but lack public confirmation of active pilots or contracts.

Sources

PUBLIC

1. [PopCheck Technologies] PopCheckTechnologies | https://popchecktechnologies.com/about-us.php

2. [CB Insights] CB Insights Company Profile | https://www.cbinsights.com/company/popcheck

3. [Science Center] The Rise of the Physician-Entrepreneur: Erika Dillard of PopCheck Technologies | https://sciencecenter.org/blog/the-rise-of-the-physician-entrepreneur-erika-dillard-of-popcheck-technologies

4. [Venture Cafe Philadelphia] Erika Dillard's Story | https://venturecafephiladelphia.org/stories/erika-dillard/

5. [University of Memphis, September 2021] UofM’s Collaborative Startup, PopCheck Technologies, Secures LaunchTN Grant | https://www.memphis.edu/research/impact/newsletter_2021/september_stories/umcollaborativestartup.php

6. [Technical.ly] This founder left Philly for Memphis. University City Science Center still calls her startup's growth a win | https://technical.ly/startups/university-city-science-center-popcheck-technologies/

7. [F6S] F6S Company Profile | https://www.f6s.com/company/popcheck-technologies-inc

8. [PitchBook] PitchBook Company Profile | https://pitchbook.com/profiles/company/489428-47

9. [Crunchbase, October 2021] BioIntelliSense Raises $45M Series B | https://www.crunchbase.com/organization/biointellisense

10. [Grand View Research, 2024] Remote Patient Monitoring Market Report | https://www.grandviewresearch.com/industry-analysis/remote-patient-monitoring-market

11. [GlobalData, 2023] Venous Thromboembolism Prevention Devices Market Report | https://www.globaldata.com/store/report/venous-thromboembolism-prevention-devices-market-analysis/

12. [American Academy of Orthopaedic Surgeons, 2023] Joint Replacement Statistics | https://www.aaos.org/news/aaosnow/apr23/clinical/clinical10/

13. [Agency for Healthcare Research and Quality] Healthcare Cost and Utilization Project (HCUP) | https://www.ahrq.gov/data/hcup/index.html

14. [Centers for Medicare & Medicaid Services] Medicare Remote Patient Monitoring Reimbursement | https://www.cms.gov/medicare/medicare-fee-for-service-payment/physicianfeesched

15. [Memphis Business Journal, June 2025] Memphis startup's wearable tech aims to rework post-surgical venous clot monitoring | https://www.bizjournals.com/memphis/news/2025/06/06/popcheck-technologies-sba-emerging-entrepreneurs.html